Tokyo Stock Exchange

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Pico Expands its Services at Japan Exchange Group Colocation Facility

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pico , a leading provider of mission-critical technology, data and analytic services for the financial markets community, continues to invest in its managed colocation facility at Japan Exchange Group, Inc. (JPX), now supporting the newly launched Layer 1 network solution.

Key Points: 
  • NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pico , a leading provider of mission-critical technology, data and analytic services for the financial markets community, continues to invest in its managed colocation facility at Japan Exchange Group, Inc. (JPX), now supporting the newly launched Layer 1 network solution.
  • The network architecture from the exchange supports ultra-low latency Layer 1 connectivity to the Tokyo Stock Exchange (TSE), Tokyo Commodity Exchange (TOCOM) and Osaka Exchange (OSE).
  • Japan is one of many global trading locations where Pico provides ultra-low latency solutions, supporting clients with latency-sensitive trading strategies that require highly accurate views of the market and fast execution times.
  • Contact us for more information about Pico’s Layer 1 network solution in the JPX data center.

CSOP Nikkei 225 Index ETF (3153.HK) to List on HKEX Tomorrow

Retrieved on: 
Tuesday, January 30, 2024

CSOP Nikkei 225 Index ETF (3153.HK) will be listed on the Hong Kong Stock Exchange on January 31, 2024, making it the first Nikkei 225 Index ETF in Hong Kong.

Key Points: 
  • CSOP Nikkei 225 Index ETF (3153.HK) will be listed on the Hong Kong Stock Exchange on January 31, 2024, making it the first Nikkei 225 Index ETF in Hong Kong.
  • View the full release here: https://www.businesswire.com/news/home/20240130677020/en/
    CSOP Nikkei 225 Index ETF (3153.HK) (Graphic: Business Wire)
    Nikkei 225 Index rose by 30% in 2023, making Japan the highest returning stock market among major global markets1.
  • CSOP Nikkei 225 Index ETF is the first ETF in Hong Kong tracking Nikkei 225 Index.
  • Ms. Ding Chen, CEO of CSOP, is pleased to announce that the CSOP Nikkei 225 Index ETF will be listed on the Hong Kong Stock Exchange tomorrow.

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Retrieved on: 
Wednesday, January 17, 2024

The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.

Key Points: 
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.
  • We are very pleased to receive a notice of this new patent which covers China and we believe it could increase the potential value of MN-166.”

EQS-News: Successful Completion of Financial Restructuring for 640 MW Yunlin Offshore Wind Farm Project in Taiwan

Retrieved on: 
Tuesday, January 2, 2024

Yunneng Wind Power Co., Ltd. (Yunneng), the company responsible for the construction and operation of the 640 MW Yunlin offshore wind farm project in Taiwan (Yunlin Project), has received the necessary approvals from Taiwanese authorities, namely, the Ministry of Economic Affairs, and Energy Administration, to enable the successful completion of its financial restructuring announced in August 2023.

Key Points: 
  • Yunneng Wind Power Co., Ltd. (Yunneng), the company responsible for the construction and operation of the 640 MW Yunlin offshore wind farm project in Taiwan (Yunlin Project), has received the necessary approvals from Taiwanese authorities, namely, the Ministry of Economic Affairs, and Energy Administration, to enable the successful completion of its financial restructuring announced in August 2023.
  • Moreover, the installation teams have reached a level of 45 monopile foundations, 26 inner array grid and 12 export cables laid.
  • The Yunlin Project is located in the Taiwan Strait, between 8 and 17 kilometers off the west coast of Taiwan, at water depths from 7 up to 35 meters.
  • Once completed, the 640 MW Yunlin Project will be one of the largest offshore wind farms in Taiwan, producing enough clean energy to serve the energy needs of more than 600,000 Taiwanese households.

Monex Group to acquire the majority stake in Canada's leading digital asset manager 3iQ

Retrieved on: 
Thursday, December 28, 2023

TOKYO and TORONTO, Dec. 28, 2023 /PRNewswire/ -- Monex Group, Inc. (Tokyo Stock Exchange, 8698), a leading Japanese financial group that runs online brokerage, crypto exchange, and asset management business in Japan and globally, will acquire the majority stake of 3iQ Digital Holdings, Inc. (together with its subsidiaries "3iQ"), a pioneer in crypto asset management in Canada.

Key Points: 
  • TOKYO and TORONTO, Dec. 28, 2023 /PRNewswire/ -- Monex Group, Inc. (Tokyo Stock Exchange, 8698), a leading Japanese financial group that runs online brokerage, crypto exchange, and asset management business in Japan and globally, will acquire the majority stake of 3iQ Digital Holdings, Inc. (together with its subsidiaries "3iQ"), a pioneer in crypto asset management in Canada.
  • In response to a dynamic market trend where major crypto asset exchanges are diversifying into asset management, 3iQ is once again leading the charge.
  • We've always been passionate about bringing regulated, innovative digital asset products to investors worldwide, and now, with Monex Group, we can turbocharge this mission.
  • For Monex Group, TD Cowen acted as financial advisor and Osler, Hoskin & Harcourt LLP as legal advisor.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Thursday, December 21, 2023

LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.

Key Points: 
  • LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah.
  • The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.
  • The presentation details are as follows:
    Abstract Number / Poster Board number: 4296 / P871
    This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Retrieved on: 
Wednesday, December 6, 2023

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
  • The allowed claims cover MN-166 (ibudilast) and interferon-beta administered in separate dosage forms, administered in the same dosage form, administered simultaneously, or administered consecutively.
  • The allowed claims specifically cover the treatment of both primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
  • The U.S. Patent and Trademark Office previously granted a similar patent covering this combination for the treatment of progressive MS."

Nidec announces investment in Gore Street Energy Storage Fund PLC, an operator of energy storage systems, for strategic partnership through Nidec’s subsidiary

Retrieved on: 
Tuesday, December 19, 2023

This pipeline will include 360 MW of projects which GSF has already announced over the next five years.

Key Points: 
  • This pipeline will include 360 MW of projects which GSF has already announced over the next five years.
  • GSF is also strengthening its portfolio, targeting markets around the world outside of its current Europe-oriented portfolio, aligning with our strategy.
  • The transaction is expected to have no significant impact on the Company’s consolidated financial performance for this fiscal year ending March 31, 2024.
  • This press release contains forward-looking statements regarding the intent, belief, strategy, plans or expectations of the Nidec Group or other parties.

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Sunday, November 19, 2023

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”